Výsledky vyhledávání

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

Publikováno v: Blood, 128(14), 1821-1828. American Society of Hematology
Blood, 128(14), 1821. American Society of Hematology
Plesner, T, Arkenau, H-T, Gimsing, P, Krejcik, J, Lemech, C, Minnema, M C, Lassen, U, Laubach, J P, Palumbo, A, Lisby, S, Basse, L, Wang, J, Sasser, A K, Guckert, M E, de Boer, C, Khokhar, N Z, Yeh, H, Clemens, P L, Ahmadi, T, Lokhorst, H M & Richardson, P G 2016, ' Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma ', Blood, vol. 128, no. 14, pp. 1821-1828 . https://doi.org/10.1182/blood-2016-07-726729

Daratumumab, a human CD38 immunoglobulin G1 kappa (IgG1κ) monoclonal antibody, has activity as monotherapy in multiple myeloma (MM). This phase 1/2 study investigated daratumumab plus lenalidomide/dexamethasone in refractory and relapsed/refractory

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4af588d173f91d363cd957f3c2d392ad
https://doi.org/10.1182/blood-2016-07-726729

Zobrazit plný text záznamu

Determination of the recommended phase II dose of birinapant in combination with pembrolizumab: Results from the dose-escalation phase of BPT-201

Autor: Malin Sydvander, Monica M. Mita, Dung T. Le, James Strauss, Richard Bethell, Siqing Fu, Linda Basse, Russell J. Schilder, Stefan Norin, Mark Albertella, Emma Boström

Publikováno v: Journal of Clinical Oncology. 37:2506-2506

2506 Background: Birinapant is a bivalent SMAC mimetic targeting cIAP1. Synergistic effects of combining birinapant with immune checkpoint inhibitors have been demonstrated in preclinical models. Based on these observations, a clinical trial with bir

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::74a29ddb475a5feb8b5eae846f621716
https://doi.org/10.1200/jco.2019.37.15_suppl.2506

Zobrazit plný text záznamu

A phase IIa study of tisotumab vedotin (HuMax®-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer

Publikováno v: Annals of Oncology. 28:v330-v331

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dd369dcedc5daf12537ca6e1d41e56a7
https://doi.org/10.1093/annonc/mdx372.001

Zobrazit plný text záznamu

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Publikováno v: Lokhorst, H M, Plesner, T, Laubach, J P, Nahi, H, Gimsing, P, Hansson, M, Minnema, M C, Lassen, U, Krejcik, J, Palumbo, A, van de Donk, N W C J, Ahmadi, T, Khan, I, Uhlar, C M, Wang, J, Sasser, A K, Losic, N, Lisby, S, Basse, L, Brun, N & Richardson, P G 2015, ' Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma ', New England Journal of Medicine, vol. 373, no. 13, pp. 1207-1219 . https://doi.org/10.1056/NEJMoa1506348
New England Journal of Medicine, 373(13), 1207. Massachussetts Medical Society
New England Journal of Medicine, 373(13), 1207-1219. Massachussetts Medical Society
Lokhorst, H M, Plesner, T, Laubach, J P, Nahi, H, Gimsing, P, Hansson, M, Minnema, M C, Lassen, U, Krejcik, J, Palumbo, A, van de Donk, N, Ahmadi, T, Khan, I, Uhlar, C M, Wang, J, Sasser, A K, Losic, N, Lisby, S, Basse, L, Brun, N & Richardson, P G 2015, ' Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma ', The New England Journal of Medicine, vol. 373, no. 13, pp. 1207-1219 . https://doi.org/10.1056/NEJMoa1506348

BACKGROUND Multiple myeloma cells uniformly overexpress CD38. We studied daratumumab, a CD38-targeting, human IgG1κ monoclonal antibody, in a phase 1–2 trial involving patients with relapsed myeloma or relapsed myeloma that was refractory to two o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b091a32c87a186a362edd84a61a4d327
https://research.vumc.nl/en/publications/2be494d7-0687-42a3-8411-f552b1cd5a84

Zobrazit plný text záznamu

Postoperative pain and gastro-intestinal recovery after colonic resection with epidural analgesia and multimodal rehabilitation

Autor: C Lund, Dorthe Hjort Jakobsen, L Gaarn-Larsen, Mads U. Werner, Linda Basse, Henrik Kehlet, Per Billesbølle

Publikováno v: Acute Pain. 7:5-11

The aim of the study was to evaluate initial postoperative pain intensity and the association with recovery of gastrointestinal function and length of stay (LOS) in a multimodal programme with epidural analgesia, early oral nutrition and mobilisation

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3b88ae72a2b607db9352ab329f2fc641
https://doi.org/10.1016/j.acpain.2005.01.001

Zobrazit plný text záznamu

Colonic Surgery With Accelerated Rehabilitation or Conventional Care

Autor: Linda Basse, Kristine Løssl, Henrik Kehlet, Jens Erik Thorbøl

Publikováno v: Diseases of the Colon & Rectum. 47:271-278

For patients undergoing colonic surgery, the postoperative hospital stay is usually 6 to 10 days, and the morbidity rate is 15 to 20 percent. Fast-track rehabilitation programs have reduced the hospital stay to 2 to 3 days. The aim of this study was

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcdc9e8ac4a2a0ae3504bd8735d3eb3b
https://doi.org/10.1007/s10350-003-0055-0

Zobrazit plný text záznamu

Gastrointestinal transit after laparoscopic versus open colonic resection

Autor: Per Billesbølle, Linda Bardram, J. L. Madsen, Henrik Kehlet, Linda Basse

Publikováno v: Surgical Endoscopy. 17:1919-1922

Background: Multimodal rehabilitation with epidural analgesia, early oral nutrition and mobilization, and laxative use has decreased the duration of ileus after colonic surgery to about 2 days, as compared with the usual 3 to 5 days of rehabilitation

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28a689a8c5c9af3cfc2e4aa0586c0ebb
https://doi.org/10.1007/s00464-003-9013-0

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání